T
T. Klingebiel
Researcher at Goethe University Frankfurt
Publications - 18
Citations - 2884
T. Klingebiel is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Acute lymphocytic leukemia & Survival rate. The author has an hindex of 12, co-authored 18 publications receiving 2571 citations. Previous affiliations of T. Klingebiel include Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
The MLL recombinome of acute leukemias.
Christian Meyer,Björn Schneider,S. Jakob,Sabine Strehl,A. Attarbaschi,Susanne Schnittger,Claudia Schoch,M W J C Jansen,J. J. M. Van Dongen,M L den Boer,Rob Pieters,M. G. Ennas,Emanuele Angelucci,Ulrike Koehl,Johann Greil,Frank Griesinger,U. Zur Stadt,C Eckert,Tomasz Szczepański,Felix Niggli,Beat W. Schäfer,Helena Kempski,Hugh J.M. Brady,Jan Zuna,Jan Trka,Luca Lo Nigro,Andrea Biondi,Eric Delabesse,Elizabeth Macintyre,Martin Stanulla,Martin Schrappe,Oskar A. Haas,Thomas Burmeister,Theodor Dingermann,T. Klingebiel,Rolf Marschalek +35 more
TL;DR: The precise localization of genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) was determined and several new TPGs were identified and two new MLL rearrangements are now characterized at the molecular level.
Journal ArticleDOI
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Anja Möricke,Alfred Reiter,Martin Zimmermann,Helmut Gadner,Martin Stanulla,Michael Dördelmann,Lutz Löning,Rita Beier,Wolf-Dieter Ludwig,Richard Ratei,Jochen Harbott,Joachim Boos,Georg Mann,Felix Niggli,Andreas Feldges,Günter Henze,Karl Welte,Jörn-Dirk Beck,T. Klingebiel,Charlotte M. Niemeyer,Felix Zintl,U. Bode,Christian Urban,Helmut Wehinger,Dietrich Niethammer,Hansjörg Riehm,Martin Schrappe +26 more
TL;DR: Consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients, and compared without previous trial ALL-BFM 90, consistently favorable results were achieved.
Journal ArticleDOI
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000
Anja Möricke,M Zimmermann,A. Reiter,Günter Henze,André Schrauder,Helmut Gadner,W.-D. Ludwig,J. Ritter,Jochen Harbott,Georg Mann,T. Klingebiel,Felix Zintl,Charlotte M. Niemeyer,Bernhard Kremens,Felix Niggli,Dietrich Niethammer,Karl Welte,Martin Stanulla,E. Odenwald,Hansjörg Riehm,Martin Schrappe +20 more
TL;DR: The major findings derived from these ALL-BFM trials were that preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX.
Journal ArticleDOI
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe,Maria Grazia Valsecchi,Claus R. Bartram,André Schrauder,Renate Panzer-Grümayer,Anja Möricke,Rosanna Parasole,Martin Zimmermann,Michael Dworzak,Barbara Buldini,Alfred Reiter,Giuseppe Basso,T. Klingebiel,Chiara Messina,Richard Ratei,Giovanni Cazzaniga,Rolf Koehler,Franco Locatelli,Beat W. Schäfer,Maurizio Aricò,Karl Welte,Jacques J.M. van Dongen,Helmut Gadner,Andrea Biondi,Valentino Conter +24 more
TL;DR: MRD ≥ 10(-3) at TP2 constitutes the most important predictive factor for relapse in childhood T-ALL, and an excellent outcome was obtained in 32% of patients turning MRD negative only at TP1, indicating that early (TP1) MRD levels were irrelevant if MRD at TP 2 was negative.
Journal ArticleDOI
New insights to the MLL recombinome of acute leukemias
Christian Meyer,Eric Kowarz,Julia Hofmann,Aline Renneville,Jan Zuna,Jan Trka,R. Ben Abdelali,Elizabeth Macintyre,E De Braekeleer,E De Braekeleer,M. De Braekeleer,M. De Braekeleer,Eric Delabesse,M. P. de Oliveira,Hélène Cavé,Emmanuelle Clappier,J J M van Dongen,Brian V. Balgobind,M M van den Heuvel-Eibrink,H B Beverloo,Renate Panzer-Grümayer,Andrea Teigler-Schlegel,Jochen Harbott,Eigil Kjeldsen,Susanne Schnittger,Ulrike Koehl,Bernd Gruhn,Olaf Heidenreich,Li Chong Chan,Sze-Fai Yip,Martin Krzywinski,C Eckert,Anja Möricke,Martin Schrappe,Cristina N. Alonso,Beat W. Schäfer,Jürgen Krauter,Dean A. Lee,U zur Stadt,G te Kronnie,Rosemary Sutton,Shai Izraeli,L. Trakhtenbrot,L. Trakhtenbrot,L Lo Nigro,Grigory Tsaur,Larisa Fechina,Tomasz Szczepański,Sabine Strehl,D. Ilencikova,Mara Molkentin,Thomas Burmeister,Theodor Dingermann,T. Klingebiel,Rolf Marschalek +54 more
TL;DR: In this paper, the distribution of MLL breakpoints for clinical subtypes (acute lymphoblastic leukemia, acute myeloid leukemia, pediatric and adult) and fused translocation partner genes (TPGs) were presented, including novel MLL fusion genes.